Prebiotic company Supergut is on a mission to improve digestion and metabolism one gut at a time. And with the rise of GLP-1 medications, consumers’ relationship with food and nutrition is changing.
“It [GLP-1s] actually is opening up the conversation about the natural approaches to try to regulate appetite, regulate blood sugar control, and I’m sure you're not surprised, but a lot of that has to do with the gut microbiome,” said Marc Washington, founder & CEO of Supergut, a panelist at IPAWC + Probiota Americas. “I call it the ‘Ozempic era', and it is giving us an opportunity to educate more people about the important role of gut health and finding natural ways to maintain, not just healthy digestion, but healthy metabolism.”
Supergut is addressing the lack of fiber in the diet of many consumers by offering prebiotic snacks, meal replacements and powders that contain resistant starch. By closing this gap, the company is able to reach a broader audience—something Washington said has increased the company’s value proposition.
“We've grown quite a bit, I would say over the past seven or eight months or so we're up about 3-4x,” Washington said. “People are hearing about gut health on the one hand and then obviously focus a lot on these GLP-1 pharmaceuticals and then seeing that there's a natural approach…it is really fascinating to a lot of people. And so that's definitely helped us build a lot of momentum.”
Washington described the current era as giving Supergut an opportunity to get back to its mission by impacting more people through its public health mission.
